Chapter 8, Prison and Health, published
Following the encouraging initial results of the pilot project, the Ministry of Health is committed to increasing access to MDR-TB diagnosis, treatment and care. An expansion plan for the programmatic management of drug-resistant TB has been developed and forms part of the Five Year National Strateg...ic Plan for TB Control, 2011-2015. The long-term goals of the MDR-TB expansion plan are threefold:
1. Diagnosis of MDR-TB in all groups of patients at risk for MDR-TB
2. Diagnosis of MDR-TB in all HIV-infected TB patients
3. MDR-TB treatment for all patients diagnosed with MDR-TB under WHO-endorsed treatment protocols
more
Эпиднадзор за состоянием окружающей среды посредством исследования сточных вод на наличие патогенных микроорганизмов давно применяется в общественном здравоох...анении, в частности, в связи с полиовирусом,
а с недавнего времени — также в связи с проблемой устойчивости к противомикробным препаратам (УПП) . В условиях
нынешней пандемии COVID-19 данная методика используется для определения в сточных водах вируса SARS-CoV-2,
выделяемого через верхние отделы желудочно-кишечного тракта и верхние дыхательные пути, а также с фекалиями.
disease control SARS-CoV-2
more
Key Populations Brief
Accessed November 2017
sthma prevalence is increasing worldwide, and surveys indicate that most patients in developed and developing countries, including South Africa, do not receive optimal care and are therefore not well controlled. Standard management guidelines adapted to in-country realities are important to support ...optimal care. The South African Thoracic Society (SATS) first published a guideline for the management of chronic persistent asthma in 1992, which has subsequently been revised several times.
The main aim of the present document was to revise and update SATS’ statement on the suggested management of chronic asthma, based on the need to promote optimal care and control of asthma, together with the incorporation of new concepts and drug developments. This revised document reinforces optimal care and incorporates the following primary objectives to achieve the recent advances in asthma care:
• continued emphasis on the use of inhaled corticosteroids (ICS) as the foundation of asthma treatment
• to reduce the reliance on short-acting beta-2 agonist (SABA) monotherapy for asthma symptoms
• to incorporate the evidence and strategy for the use of the combination of an ICS and formoterol for acute symptom relief (instead of a SABA)
• to incorporate the evidence and strategy for the use of as-needed ICS-long-acting beta agonists (LABA) for patients with infrequent symptoms or ‘mild’ asthma
• to incorporate the evidence and strategy for the use of a long-acting muscarinic antagonist (LAMA) in combination with ICS-LABA; and
• to incorporate the evidence and strategy for the use of and management with a biologic therapy in severe asthma.
more
Research
Emerging Infectious Diseases Vol. 12, No. 5, May 2006
Lancet Respir Med 2017; 5: 291–360Vol, 5 April 2017
Emerging Infectious Diseases; Vol. 21, No. 11, November 2015